Fulvestrant

Breast, Malignant Neoplasms, PI3K Gene Mutation + 4 more

Treatment

8 FDA approvals

1 Active Study for Fulvestrant

What is Fulvestrant

Fulvestrant

The Generic name of this drug

Treatment Summary

Fulvestrant is a type of hormone therapy used to treat breast cancer in post-menopausal women whose cancer has progressed despite taking anti-estrogen medications. It works by blocking and destroying the estrogen receptor, which helps slow the growth of the cancer. It is most often used as a single drug treatment but may also be combined with alpelisib for certain types of breast cancer.

Faslodex

is the brand name

image of different drug pills on a surface

Fulvestrant Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Faslodex

Fulvestrant

2010

29

Approved as Treatment by the FDA

Fulvestrant, commonly known as Faslodex, is approved by the FDA for 8 uses which include Progression, Disease and Advanced or Metastatic Breast Cancer .

Progression, Disease

Used to treat Progression, Disease in combination with Abemaciclib

Advanced or Metastatic Breast Cancer

Used to treat Advanced or Metastatic Breast Cancer in combination with Abemaciclib

PI3K Gene Mutation

Used to treat PI3K Gene Mutation in combination with Alpelisib

Disease

Used to treat disease progression after endocrine based therapy in combination with Alpelisib

PIK3CA Gene Mutation

Used to treat PIK3CA Gene Mutation in combination with Alpelisib

Malignant Neoplasms

Used to treat Advanced or Metastatic Breast Cancer in combination with Abemaciclib

Disease Progression

Used to treat Progression, Disease in combination with Abemaciclib

prior endocrine therapy

Used to treat prior endocrine therapy in combination with Abemaciclib

Effectiveness

How Fulvestrant Affects Patients

Fulvestrant is a type of medicine given by injection that blocks the action of the hormone estrogen. It does not have any known effects that imitate estrogen.

How Fulvestrant works in the body

Fulvestrant is used to treat estrogen-sensitive breast cancer. It works by blocking the estrogen receptors in cancer cells. This prevents estrogen from binding to these receptors, and also causes them to break down. This helps stop the growth of cancers that are resistant to tamoxifen, as well as those that are sensitive to estrogen.

When to interrupt dosage

The proposed dosage of Fulvestrant is contingent upon the identified condition, including Progression, Disease, Breast and PIK3CA Gene Mutation. The volume of dosage is contingent upon the mode of delivery (e.g. Solution or Injection), which has been defined in the table below.

Condition

Dosage

Administration

Breast

, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg

Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection

PIK3CA Gene Mutation

, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg

Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection

Malignant Neoplasms

, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg

Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection

PI3K Gene Mutation

, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg

Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection

Disease Progression

, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg

Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection

Disease

, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg

Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection

prior endocrine therapy

, 250.0 mg/mL, 50.0 mg/mL, 250.0 mg

Solution - Intramuscular, Solution, , Intramuscular, Injection, solution, Injection, solution - Intramuscular, Injection - Intramuscular, Injection

Warnings

There are 2 known major drug interactions with Fulvestrant.

Common Fulvestrant Drug Interactions

Drug Name

Risk Level

Description

Ospemifene

Major

The risk or severity of adverse effects can be increased when Fulvestrant is combined with Ospemifene.

Fluoroestradiol F-18

Moderate

Fulvestrant may decrease effectiveness of Fluoroestradiol F-18 as a diagnostic agent.

Fulvestrant Toxicity & Overdose Risk

There is no known experience of overdosing on this drug in humans.

image of a doctor in a lab doing drug, clinical research

Fulvestrant Novel Uses: Which Conditions Have a Clinical Trial Featuring Fulvestrant?

At present, 20 clinical trials are assessing the potential of Fulvestrant to inhibit Progression of Disease, Breast Cancer and Malignant Neoplasms.

Condition

Clinical Trials

Trial Phases

Breast

0 Actively Recruiting

Malignant Neoplasms

0 Actively Recruiting

Disease

0 Actively Recruiting

PIK3CA Gene Mutation

0 Actively Recruiting

Disease Progression

0 Actively Recruiting

PI3K Gene Mutation

1 Actively Recruiting

Phase 1

prior endocrine therapy

0 Actively Recruiting

Fulvestrant Reviews: What are patients saying about Fulvestrant?

4

Patient Review

10/25/2013

Fulvestrant for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy

So far, I've had two rounds of injections with only minor side effects like insomnia and a sore throat. Fingers crossed that this continues to be an effective treatment for me with no major complications.

4

Patient Review

10/30/2017

Fulvestrant for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy

I am currently on my sixth cycle of this protocol (Fluvestrant with Taselisib) and, so far, it is working well. My doctors tell me that the cancer is 'stable,' which is good news. I am hopeful that the tumors will disappear completely soon. In the meantime, I have learned to relax during treatment and Visualize the tumors disappearing, which has helped reduce the pain significantly.

3.7

Patient Review

6/5/2013

Fulvestrant for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy

I've been taking this for a couple years now. It's less painful if you heat it up first and administer it slowly. Over time, it became less painful for me in general. Additionally, it halted the growth of my tumor and helped me feel overall healthier--I'm really glad I use this treatment! That said, I do wish it came in pill form.

1.7

Patient Review

9/25/2009

Fulvestrant for Metastatic Breast Cancer Progression Post-Antiestrogen Therapy

I just started this last week and had my first treatment.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about fulvestrant

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long can you take fulvestrant?

"Fulvestrant is most commonly given to patients in hospitals every two weeks for the first three doses, and then once a month. Fulvestrant is often given to patients for as long as it is successful in controlling their breast cancer and any side effects can be managed."

Answered by AI

Is fulvestrant a chemotherapy?

"Faslodex is a hormonal therapy that blocks estrogen receptors in the body, which may help to treat breast cancer. Faslodex can be used alone or in combination with other medications."

Answered by AI

What are the side effects of fulvestrant?

"If you experience any of the following symptoms, you should see a doctor as soon as possible: black or tarry stools, bloating or swelling of the face, arms, hands, lower legs, or feet, blood in the urine or stools, chest pain or tightness, cloudy urine, difficulty breathing, hoarseness, or irregular heartbeat."

Answered by AI

What type of drug is fulvestrant?

"Fulvestrant is a type of medication that works by blocking the action of estrogen on cancer cells, which can slow or stop the growth of some breast tumors that need estrogen to grow."

Answered by AI

Clinical Trials for Fulvestrant